Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

09-275 Anti-phospho-JAK2 (Tyr1007/1008) Antibody

09-275
200 µL  
Purchase on Sigma-Aldrich

特卖

概述

Replacement Information

重要规格表

Species ReactivityKey ApplicationsHostFormatAntibody Type
H, Ch, M, Po, R, Xn, ZebrafishWBRbAffinity PurifiedPolyclonal Antibody
Description
Catalogue Number09-275
Replaces04-1098
DescriptionAnti-phospho-JAK2 (Tyr1007/1008) Antibody
Alternate Names
  • Tyrosine-protein kinase JAK2
  • Janus kinase 2
  • JAK-2
Background InformationJanus kinase 2 (JAK2) is a ubiquitous non-receptor tyrosine kinase that interacts with multiple cell-surface receptors and non-receptor proteins to affect a range of cellular processes including immunity, cell growth, development, and differentiation. Among JAK2’s receptor partners are the prolactin, growth hormone, thrombopoitin, and INF (α and β) receptors. JAK2 plays an important role in connecting the signaling pathways of these receptors to the activation of target genes. Upon ligand binding these receptors activate JAK2 inducing JAK2 autophosphorylation; This activated JAK2 in turn phosphorylates the cytoplasmic domains of these receptors providing a binding site for STAT transcription factors which are also phosphorylated by JAK2 leading to STAT protein dimerization and translocation to the nucleus to effect gene transcription. Aberrations in JAK2 expression and function may contribute to myelofibrosis and myelogenous leukemia.
References
Product Information
FormatAffinity Purified
Control
  • LPS/IFN gamma untreated and treated RAW264.7 cell lysates
PresentationPurified rabbit polyclonal serum in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl, and 0.05% sodium azide.
Quality LevelMQ100
Applications
ApplicationAnti-phospho-JAK2 (Tyr1007/1008) Antibody is an antibody against phospho-JAK2 (Tyr1007/1008) for use in WB.
Key Applications
  • Western Blotting
Biological Information
ImmunogenKLH-conjugated linear peptide corresponding to human JAK2 phosphorylated at (Tyr1007/Tyr1008).
EpitopePhosphorylated (Tyr1007/Tyr1008)
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostRabbit
SpecificityThis antibody recognizes JAK2 phosphorylated at (Tyr1007/Tyr1008).
Species Reactivity
  • Human
  • Chicken
  • Mouse
  • Pig
  • Rat
  • Xenopus
  • Zebrafish
Species Reactivity NoteDemonstrated to react with Mouse. Predicted to react with Human, Rat, Porcine, Xenopus, Chicken, and Zebra fish based on 100% sequence homology.
Antibody TypePolyclonal Antibody
Entrez Gene Number
Entrez Gene SummaryThis gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq, Jul 2008].
Gene Symbol
  • JAK2
Purification MethodAffinity Purfied
UniProt Number
UniProt SummaryFUNCTION: Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin. CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.

ENZYME REGULATION: Regulated by autophosphorylation, can both activate or decrease activity (By similarity). Heme regulates its activity by enhancing the phosphorylation on Tyr-1007 and Tyr-1008.

SUBUNIT STRUCTURE: Interacts with EPOR, LYN, SIRPA, SH2B1 and TEC (By similarity). Interacts with IL23R, SKB1 and STAM2.

SUBCELLULAR LOCATION: Endomembrane system; Peripheral membrane protein (By similarity). Cytoplasm. Nucleus

TISSUE SPECIFICITY: Ubiquitously expressed throughout most tissues.

DOMAIN: Possesses 2 protein kinase domains. The second one probably contains the catalytic domain, while the presence of slight differences suggest a different role for protein kinase 1 (By similarity).

PTM: Autophosphorylated, leading to regulate its activity. Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813. Autophosphorylation on Tyr-119 in response to EPO down-regulates its kinase activity. Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972 in response to growth hormone (GH) are required for maximal kinase activity. Also phosphorylated by TEC (By similarity).

INVOLVEMENT IN DISEASE: Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.

Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BDCHS) [MIM:600880]. A syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera.

Defects in JAK2 are a cause of polycythemia vera (PV) [MIM:263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.

Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.

Defects in JAK2 are a cause of myelofibrosis (MYELOF) [MIM:254450]. Myelofibrosis is a disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.

Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.

SEQUENCE SIMILARITIES: Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.

Contains 1 FERM domain.

Contains 1 protein kinase domain.

Contains 1 SH2 domain.
Molecular Weight~130 kDa observed. Uncharacterized bands appear at ~48, 55, 65, and 100 kDa in some lysates.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceEvaluated by Western Blot in LPS/IFN gamma untreated and treated RAW264.7 cell lysates.

Western Blot Analysis: A 1:5,000 dilution of this antibody detected JAK2 on 10 µg of LPS/IFN gamma untreated and treated RAW264.7 cell lysates.
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStable for 1 year at 2-8°C from date of receipt.
Packaging Information
Material Size200 µL
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
产品目录编号 GTIN
09-275 04053252408014

Documentation

Anti-phospho-JAK2 (Tyr1007/1008) Antibody MSDS

职位

物料安全数据表 (MSDS) 

Anti-phospho-JAK2 (Tyr1007/1008) Antibody 分析证书

标题批号
Anti-20S proteasome subunit 5 -2567481 2567481
Anti-Phospho-JAK2 (Tyr1007/Tyr1008) - 2433408 2433408
Anti-Phospho-JAK2 (Tyr1007/Tyr1008) - 1959262 1959262
Anti-Phospho-JAK2 (Tyr1007/Tyr1008) - 2199006 2199006
Anti-Phospho-JAK2 (Tyr1007/Tyr1008) - 2329789 2329789
Anti-Phospho-JAK2 (Tyr1007/Tyr1008) - 3383967 3383967
Anti-Phospho-JAK2 (Tyr1007/Tyr1008) - 3425760 3425760
Anti-Phospho-JAK2 (Tyr1007/Tyr1008) - 3468889 3468889
Anti-Phospho-JAK2 (Tyr1007/Tyr1008) - 3692650 3692650
Anti-Phospho-JAK2 (Tyr1007/Tyr1008) - 3978864 3978864

参考

参考概述公共医疗ID
15-Lipoxygenase-1-enhanced Src-Janus kinase 2-signal transducer and activator of transcription 3 stimulation and monocyte chemoattractant protein-1 expression require redox-sensitive activation of epidermal growth factor receptor in vascular wall remodeling.
Singh, NK; Wang, D; Kundumani-Sridharan, V; Van Quyen, D; Niu, J; Rao, GN
The Journal of biological chemistry  286  22478-88  2011

显示摘要
21536676 21536676
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott, Linda M, et al.
N. Engl. J. Med., 356: 459-68 (2007)  2007

显示摘要
17267906 17267906
The membrane-proximal region of the thrombopoietin receptor confers its high surface expression by JAK2-dependent and -independent mechanisms
Tong, Wei, et al
J Biol Chem, 281:38930-40 (2006)  2006

17052978 17052978
Differential effects of lipoprotein lipase on tumor necrosis factor-alpha and interferon-gamma-mediated gene expression in human endothelial cells
Kota, Rama S, et al
J Biol Chem, 280:31076-84 (2005)  2005

15994321 15994321

技术信息

标题
JAK/STAT Signaling Research Focus